The dopamine agonists market size has grown strongly in recent years. It will grow from $2.73 billion in 2025 to $2.93 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing prevalence of parkinson’s disease, early clinical success of dopamine therapies, limited alternatives for movement disorders, expansion of neurology care centers, improved diagnostic rates.
The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to $3.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to aging global population, rising neurological disorder burden, demand for improved motor symptom control, growth of home-based neurological care, development of patient-friendly formulations. Major trends in the forecast period include rising use in parkinson’s disease management, growing adoption of non-ergot dopamine agonists, increased preference for long-acting formulations, expansion of transdermal delivery options, higher utilization in restless legs syndrome.
The increasing prevalence of neurological disorders is expected to drive the growth of the dopamine agonist market. Neurological disorders are medical conditions that impact the brain, spine, or nerves, leading to difficulties with movement, cognition, or behavior. This rising prevalence is partly attributed to longer life expectancies, as the likelihood of developing conditions such as Alzheimer's and Parkinson's increases with age. Dopamine agonists are used to manage neurological disorders like Parkinson's disease by stimulating dopamine receptors in the brain, enhancing motor control, and alleviating symptoms. For example, in 2024, according to the Alzheimer's Disease Facts and Figures report by the Alzheimer's Association, a US-based nonprofit organization dedicated to Alzheimer's care, support, and research, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia in 2022, which rose to 6.9 million in 2024. Consequently, the growing prevalence of neurological disorders is anticipated to propel the expansion of the dopamine agonist market.
Major companies operating in the dopamine agonists market are emphasizing innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more personalized treatment options for neurological disorders. Flexible-dose monotherapy is a therapeutic approach that utilizes a single medication with adjustable dosing, enabling physicians to customize the dosage according to each patient's specific needs and response. For example, in December 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive topline results from its Phase 3 TEMPO-2 trial, showing that the investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), significantly improved motor function in patients with early Parkinson's disease. The trial met its primary endpoint with a notable reduction in MDS-UPDRS Parts II and III scores and achieved key secondary endpoints, demonstrating meaningful improvement in daily motor activities. Tavapadon is the first D1/D5 partial agonist being evaluated for once-daily Parkinson's treatment.
In August 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. Through this acquisition, AbbVie intends to enhance its neuroscience portfolio by obtaining access to Cerevel Therapeutics' innovative pipeline of treatments for neurological and psychiatric disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for psychiatric and neurological conditions.
Major companies operating in the dopamine agonists market are Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Luye Pharma Group Ltd., Kissei Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Mylan N.V., Sandoz Group AG, Hikma Pharmaceuticals PLC, Apotex Inc., Alkem Laboratories Ltd.
North America was the largest region in the dopamine agonists market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dopamine agonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the dopamine agonists market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and specialized excipients used in neurological drugs. These impacts have been most pronounced in branded and transdermal segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have experienced pricing pressure and supply chain disruptions due to trade dependencies. However, tariffs have supported domestic API production and local formulation development, enhancing regional supply continuity.
The dopamine agonists market research report is one of a series of new reports that provides dopamine agonists market statistics, including dopamine agonists industry global market size, regional shares, competitors with a dopamine agonists market share, detailed dopamine agonists market segments, market trends and opportunities, and any further data you may need to thrive in the dopamine agonists industry. This dopamine agonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Dopamine agonists are drugs that stimulate dopamine receptors in the brain, imitating the actions of natural dopamine. They are employed to treat conditions resulting from reduced dopamine activity or disrupted dopamine signaling.
The primary categories of dopamine agonists include ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are drugs derived from ergot alkaloids that stimulate dopamine receptors in the brain to assist in managing neurological and hormonal disorders. They are available in multiple forms of administration, including oral, parenteral, and transdermal patches. These drugs are supplied through various distribution channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. They are utilized for several conditions, including Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. The main end users consist of hospitals, clinics, and home care environments.
The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to $3.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to aging global population, rising neurological disorder burden, demand for improved motor symptom control, growth of home-based neurological care, development of patient-friendly formulations. Major trends in the forecast period include rising use in parkinson’s disease management, growing adoption of non-ergot dopamine agonists, increased preference for long-acting formulations, expansion of transdermal delivery options, higher utilization in restless legs syndrome.
The increasing prevalence of neurological disorders is expected to drive the growth of the dopamine agonist market. Neurological disorders are medical conditions that impact the brain, spine, or nerves, leading to difficulties with movement, cognition, or behavior. This rising prevalence is partly attributed to longer life expectancies, as the likelihood of developing conditions such as Alzheimer's and Parkinson's increases with age. Dopamine agonists are used to manage neurological disorders like Parkinson's disease by stimulating dopamine receptors in the brain, enhancing motor control, and alleviating symptoms. For example, in 2024, according to the Alzheimer's Disease Facts and Figures report by the Alzheimer's Association, a US-based nonprofit organization dedicated to Alzheimer's care, support, and research, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia in 2022, which rose to 6.9 million in 2024. Consequently, the growing prevalence of neurological disorders is anticipated to propel the expansion of the dopamine agonist market.
Major companies operating in the dopamine agonists market are emphasizing innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more personalized treatment options for neurological disorders. Flexible-dose monotherapy is a therapeutic approach that utilizes a single medication with adjustable dosing, enabling physicians to customize the dosage according to each patient's specific needs and response. For example, in December 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive topline results from its Phase 3 TEMPO-2 trial, showing that the investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), significantly improved motor function in patients with early Parkinson's disease. The trial met its primary endpoint with a notable reduction in MDS-UPDRS Parts II and III scores and achieved key secondary endpoints, demonstrating meaningful improvement in daily motor activities. Tavapadon is the first D1/D5 partial agonist being evaluated for once-daily Parkinson's treatment.
In August 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. Through this acquisition, AbbVie intends to enhance its neuroscience portfolio by obtaining access to Cerevel Therapeutics' innovative pipeline of treatments for neurological and psychiatric disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for psychiatric and neurological conditions.
Major companies operating in the dopamine agonists market are Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Luye Pharma Group Ltd., Kissei Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Hetero Drugs Ltd., Mylan N.V., Sandoz Group AG, Hikma Pharmaceuticals PLC, Apotex Inc., Alkem Laboratories Ltd.
North America was the largest region in the dopamine agonists market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dopamine agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dopamine agonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the dopamine agonists market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and specialized excipients used in neurological drugs. These impacts have been most pronounced in branded and transdermal segments, particularly in north america and europe where API sourcing is globally diversified. Asia-pacific manufacturers have experienced pricing pressure and supply chain disruptions due to trade dependencies. However, tariffs have supported domestic API production and local formulation development, enhancing regional supply continuity.
The dopamine agonists market research report is one of a series of new reports that provides dopamine agonists market statistics, including dopamine agonists industry global market size, regional shares, competitors with a dopamine agonists market share, detailed dopamine agonists market segments, market trends and opportunities, and any further data you may need to thrive in the dopamine agonists industry. This dopamine agonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Dopamine agonists are drugs that stimulate dopamine receptors in the brain, imitating the actions of natural dopamine. They are employed to treat conditions resulting from reduced dopamine activity or disrupted dopamine signaling.
The primary categories of dopamine agonists include ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are drugs derived from ergot alkaloids that stimulate dopamine receptors in the brain to assist in managing neurological and hormonal disorders. They are available in multiple forms of administration, including oral, parenteral, and transdermal patches. These drugs are supplied through various distribution channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. They are utilized for several conditions, including Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. The main end users consist of hospitals, clinics, and home care environments.
The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Dopamine Agonists Market Characteristics
3. Dopamine Agonists Market Supply Chain Analysis
4. Global Dopamine Agonists Market Trends and Strategies
5. Dopamine Agonists Market Analysis of End Use Industries
7. Global Dopamine Agonists Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Dopamine Agonists Total Addressable Market (TAM) Analysis for the Market
9. Dopamine Agonists Market Segmentation
10. Dopamine Agonists Market Regional and Country Analysis
11. Asia-Pacific Dopamine Agonists Market
12. China Dopamine Agonists Market
13. India Dopamine Agonists Market
14. Japan Dopamine Agonists Market
15. Australia Dopamine Agonists Market
16. Indonesia Dopamine Agonists Market
17. South Korea Dopamine Agonists Market
18. Taiwan Dopamine Agonists Market
19. South East Asia Dopamine Agonists Market
20. Western Europe Dopamine Agonists Market
21. UK Dopamine Agonists Market
22. Germany Dopamine Agonists Market
23. France Dopamine Agonists Market
24. Italy Dopamine Agonists Market
25. Spain Dopamine Agonists Market
26. Eastern Europe Dopamine Agonists Market
27. Russia Dopamine Agonists Market
28. North America Dopamine Agonists Market
29. USA Dopamine Agonists Market
30. Canada Dopamine Agonists Market
31. South America Dopamine Agonists Market
32. Brazil Dopamine Agonists Market
33. Middle East Dopamine Agonists Market
34. Africa Dopamine Agonists Market
36. Dopamine Agonists Market Competitive Landscape and Company Profiles
37. Dopamine Agonists Market Other Major and Innovative Companies
40. Dopamine Agonists Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Dopamine Agonists Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses dopamine agonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for dopamine agonists? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dopamine agonists market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Ergot Based Dopamine Agonists; Non Ergot Based Dopamine Agonists2) By Route of Administration: Oral; Parenteral; Transdermal Patches
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
4) By Application: Parkinson's Disease; Restless Legs Syndrome (RLS); Hyperprolactinemia
5) By End User: Hospitals; Clinics; Home Care Settings
Subsegments:
1) By Ergot-Based Dopamine Agonists: Bromocriptine; Cabergoline; Pergolide2) By Non-Ergot-Based Dopamine Agonists: Pramipexole; Ropinirole; Rotigotine; Apomorphine
Companies Mentioned: Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; Dr. Reddy’s Laboratories Ltd.; Lupin Limited; Luye Pharma Group Ltd.; Kissei Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Cipla Limited; Torrent Pharmaceuticals Ltd.; Zydus Lifesciences Ltd.; Glenmark Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Hetero Drugs Ltd.; Mylan N.V.; Sandoz Group AG; Hikma Pharmaceuticals PLC; Apotex Inc.; Alkem Laboratories Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Dopamine Agonists market report include:- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Lupin Limited
- Luye Pharma Group Ltd.
- Kissei Pharmaceutical Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Cipla Limited
- Torrent Pharmaceuticals Ltd.
- Zydus Lifesciences Ltd.
- Glenmark Pharmaceuticals Ltd.
- Alembic Pharmaceuticals Ltd.
- Hetero Drugs Ltd.
- Mylan N.V.
- Sandoz Group AG
- Hikma Pharmaceuticals PLC
- Apotex Inc.
- Alkem Laboratories Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.93 Billion |
| Forecasted Market Value ( USD | $ 3.86 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
